Pioglitazone吡格列酮,111025-46-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Pioglitazone

CAS No. : 111025-46-8

MCE 国际站：Pioglitazone

产品活性：Pioglitazone (U 72107) 是一种具有口服活性的选择性 PPARγ (peroxisome proliferator-activated receptor) 激动剂，高亲和力结合到 PPARγ 配体结合域，作用于人和鼠 PPARγ 的 EC₅₀ 分别为 0.93 和 0.99 μM。Pioglitazone 可用于糖尿病研究。

研究领域：Cell Cycle/DNA Damage  |  Vitamin D Related/Nuclear Receptor  |  Apoptosis

作用靶点：PPAR  |  Ferroptosis

In Vitro: Pioglitazone (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15.
?Pioglitazone (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs.

In Vivo: Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle.
?Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-diabetic Compound Library  |  Ferroptosis Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Transcription Factor-Targeted Library  |  Lipid Metabolism Compound Library   |  Tumorigenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Antidepressant Compound Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Nuclear Receptor Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Osteogenesis Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  Mitochondrial Protection Compound Library  |  Mitochondrial Toxicity Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cell Death Library  |  Ferrostatin-1  |  Erastin  |  Cisplatin  |  Cycloheximide  |  RSL3  |  Acetylcysteine  |  Sorafenib  |  ML385  |  Necrostatin-1  |  Retinoic acid  |  SP600125  |  Rosiglitazone  |  Liproxstatin-1  |  Curcumin  |  GW9662  |  Simvastatin  |  Hemin  |  TBHQ  |  Lapatinib  |  Roxadustat  |  L-Glutathione reduced  |  Trolox  |  Lovastatin  |  Sulfasalazine  |  NADPH tetrasodium salt  |  U-73122  |  Pifithrin-α hydrobromide  |  iFSP1  |  Atorvastatin hemicalcium salt  |  Fenofibrate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds